Patents Assigned to Jazz Pharmaceuticals, Inc.
-
Publication number: 20140207481Abstract: A drug distribution system and method utilizes a central pharmacy and database to track all prescriptions for a sensitive drug. Information is kept in the database regarding all physicians allowed to prescribe the sensitive drug, and all patients receiving the drug. Abuses are identified by monitoring data in the database for prescription patterns by physicians and prescriptions obtained by patients. Further verification is made that the physician is eligible to prescribe the drug by consulting a separate database, and optionally whether any actions are taken against the physician. Multiple controls beyond those for normal drugs are imposed on the distribution depending on the sensitivity of the drug.Type: ApplicationFiled: March 19, 2014Publication date: July 24, 2014Applicant: Jazz Pharmaceuticals, Inc.Inventors: Dayton T. Reardan, Patti A. Engel, Bob Gagne
-
Publication number: 20140207480Abstract: A drug distribution system and method utilizes a central pharmacy and database to track all prescriptions for a sensitive drug. Information is kept in the database regarding all physicians allowed to prescribe the sensitive drug, and all patients receiving the drug. Abuses are identified by monitoring data in the database for prescription patterns by physicians and prescriptions obtained by patients. Further verification is made that the physician is eligible to prescribe the drug by consulting a separate database, and optionally whether any actions are taken against the physician. Multiple controls beyond those for normal drugs are imposed on the distribution depending on the sensitivity of the drug.Type: ApplicationFiled: March 19, 2014Publication date: July 24, 2014Applicant: Jazz Pharmaceuticals, Inc.Inventors: Dayton T. Reardan, Patti A. Engel, Bob Gagne
-
Patent number: 8778398Abstract: The present invention provides a solid immediate release dosage form adapted for oral administration of GHB. The solid immediate release dosage form includes an immediate release formulation comprising a relatively high weight-percentage of GHB with a bioavailability similar to that of a liquid GHB dosage form.Type: GrantFiled: May 4, 2010Date of Patent: July 15, 2014Assignee: Jazz Pharmaceuticals, Inc.Inventors: Andrea Marie Rourke, Maura Patricia Murphy, James Frederick Pfeiffer, Clark Patrick Allphin, Alya Khan McGinlay
-
Patent number: 8772306Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.Type: GrantFiled: April 29, 2013Date of Patent: July 8, 2014Assignee: Jazz Pharmaceuticals, Inc.Inventor: Mark Eller
-
Patent number: 8771735Abstract: The present invention provides a pharmaceutical composition, presented as a solid unit dosage form adapted for oral administration of sodium oxybate. The preferred unit dosage form is a tablet comprising a relatively high weight-percentage of sodium oxybate, in combination with a relatively small weight-percentage of total excipients. This permits the tablets to contain/deliver a pharmaceutically effective amount, e.g., about 0.5-1.5 g of sodium oxybate in each tablet with a delivery profile similar to that of the liquid form. The tablets are bioequivalent to the liquid form.Type: GrantFiled: November 4, 2008Date of Patent: July 8, 2014Assignee: Jazz Pharmaceuticals, Inc.Inventors: Andrea Rourke, Clark Allphin, Maura Murphy
-
Publication number: 20140188504Abstract: A drug distribution system and method utilizes a central pharmacy and database to track all prescriptions for a sensitive drug. Information is kept in the database regarding all physicians allowed to prescribe the sensitive drug, and all patients receiving the drug. Abuses are identified by monitoring data in the database for prescription patterns by physicians and prescriptions obtained by patients. Further verification is made that the physician is eligible to prescribe the drug by consulting a separate database, and optionally whether any actions are taken against the physician. Multiple controls beyond those for normal drugs are imposed on the distribution depending on the sensitivity of the drug.Type: ApplicationFiled: March 4, 2014Publication date: July 3, 2014Applicant: Jazz Pharmaceuticals, Inc.Inventors: Dayton T. Reardan, Patti A. Engel, Bob Gagne
-
Publication number: 20140171506Abstract: Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.Type: ApplicationFiled: February 4, 2014Publication date: June 19, 2014Applicant: Jazz Pharmaceuticals, Inc.Inventors: Clark P. Allphin, Michael DesJardin
-
Publication number: 20140171505Abstract: Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.Type: ApplicationFiled: October 3, 2013Publication date: June 19, 2014Applicant: Jazz Pharmaceuticals, Inc.Inventors: Clark P. Allphin, Michael DesJardin
-
Patent number: 8731963Abstract: A drug distribution system and method utilizes a central pharmacy and database to track all prescriptions for a sensitive drug. Information is kept in the database regarding all physicians allowed to prescribe the sensitive drug, and all patients receiving the drug. Abuses are identified by monitoring data in the database for prescription patterns by physicians and prescriptions obtained by patients. Further verification is made that the physician is eligible to prescribe the drug by consulting a separate database, and optionally whether any actions are taken against the physician. Multiple controls beyond those for normal drugs are imposed on the distribution depending on the sensitivity of the drug.Type: GrantFiled: August 22, 2012Date of Patent: May 20, 2014Assignee: Jazz Pharmaceuticals, Inc.Inventors: Dayton T. Reardan, Patti A. Engel, Bob Gagne
-
Patent number: 8716279Abstract: The present invention includes benzodiazepine compositions formulated for intranasal administration, comprising a binary solvent system comprising a first solvent in which the benzodiazepine is soluble, the first solvent capable of penetrating nasal mucosal tissue, and a second solvent in which the benzodiazepine in less soluble. The compositions of the present invention may be used to treat a variety of disorders including, but not limited to, panic attacks, muscle spasms, anxiety, and seizures. In one aspect, the present invention relates to a fast-acting, clonazepam composition for transnasal administration that can be used for the treatment of seizure clusters.Type: GrantFiled: August 27, 2007Date of Patent: May 6, 2014Assignee: Jazz Pharmaceuticals, Inc.Inventors: Gene Jamieson, Michael Des Jardin, Clark Allphin, Sigridur Olafsdottir
-
Patent number: 8609651Abstract: The present invention includes benzodiazepine compositions formulated for intranasal administration, comprising a binary solvent system comprising a first solvent in which the benzodiazepine is soluble, the first solvent capable of penetrating nasal mucosal tissue, and a second solvent in which the benzodiazepine in less soluble. The compositions of the present invention may be used to treat a variety of disorders including, but not limited to, panic attacks, muscle spasms, anxiety, and seizures. In one aspect, the present invention relates to a fast-acting, clonazepam composition for transnasal administration that can be used for the treatment of seizure clusters.Type: GrantFiled: August 27, 2007Date of Patent: December 17, 2013Assignee: Jazz Pharmaceuticals, Inc.Inventors: Gene Jamieson, Michael Des Jardin, Clark Allphin, Sigridur Olafsdottir
-
Patent number: 8589182Abstract: A drug distribution system and method utilizes a central pharmacy and database to track all prescriptions for a sensitive drug. Information is kept in the database regarding all physicians allowed to prescribe the sensitive drug, and all patients receiving the drug. Abuses are identified by monitoring data in the database for prescription patterns by physicians and prescriptions obtained by patients. Further verification is made that the physician is eligible to prescribe the drug by consulting a separate database, and optionally whether any actions are taken against the physician. Multiple controls beyond those for normal drugs are imposed on the distribution depending on the sensitivity of the drug.Type: GrantFiled: August 27, 2012Date of Patent: November 19, 2013Assignee: Jazz Pharmaceuticals, Inc.Inventors: Dayton T. Reardan, Patti A. Engel, Bob Gagne
-
Publication number: 20130267595Abstract: Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.Type: ApplicationFiled: March 6, 2013Publication date: October 10, 2013Applicant: Jazz Pharmaceuticals, Inc.Inventors: Harry Cook, Martha Hamilton, Douglas Danielson, Colette Goderstad, Dayton T. Reardan
-
Patent number: 8461203Abstract: Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.Type: GrantFiled: July 13, 2011Date of Patent: June 11, 2013Assignee: Jazz Pharmaceuticals, Inc.Inventors: Harry Cook, Martha Hamilton, Douglas Danielson, Colette Goderstad, Dayton T. Reardan
-
Publication number: 20130143965Abstract: Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.Type: ApplicationFiled: November 26, 2012Publication date: June 6, 2013Applicant: Jazz Pharmaceuticals, Inc.Inventors: Harry Cook, Martha Hamilton, Douglas Danielson, Colette Goderstad, Dayton T. Reardan
-
Patent number: 8457988Abstract: A drug distribution system and method utilizes a central pharmacy and database to track all prescriptions for a sensitive drug. Information is kept in the database regarding all physicians allowed to prescribe the sensitive drug, and all patients receiving the drug. Abuses are identified by monitoring data in the database for prescription patterns by physicians and prescriptions obtained by patients. Further verification is made that the physician is eligible to prescribe the drug by consulting a separate database, and optionally whether any actions are taken against the physician. Multiple controls beyond those for normal drugs are imposed on the distribution depending on the sensitivity of the drug.Type: GrantFiled: August 27, 2012Date of Patent: June 4, 2013Assignee: Jazz Pharmaceuticals, Inc.Inventors: Dayton T. Reardan, Patti A. Engel, Bob Gagne
-
Patent number: 8324275Abstract: Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gammahydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.Type: GrantFiled: April 13, 2012Date of Patent: December 4, 2012Assignee: Jazz Pharmaceuticals, Inc.Inventors: Harry Cook, Martha Hamilton, Douglas Danielson, Colette Goderstad, Dayton T. Reardan
-
Patent number: 8263650Abstract: Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gammahydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.Type: GrantFiled: April 13, 2012Date of Patent: September 11, 2012Assignee: Jazz Pharmaceuticals, Inc.Inventors: Harry Cook, Martha Hamilton, Douglas Danielson, Colette Goderstad, Dayton T. Reardan
-
Publication number: 20120202879Abstract: Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gammahydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.Type: ApplicationFiled: April 13, 2012Publication date: August 9, 2012Applicant: Jazz Pharmaceuticals, Inc.Inventors: Harry Cook, Martha Hamilton, Douglas Danielson, Colette Goderstad, Dayton Reardan
-
Publication number: 20120202880Abstract: Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gammahydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.Type: ApplicationFiled: April 13, 2012Publication date: August 9, 2012Applicant: Jazz Pharmaceuticals, Inc.Inventors: Harry Cook, Martha Hamilton, Douglas Danielson, Colette Goderstad, Dayton Reardan